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Background. Isolated growth hormone deficiency (IGHD) and multiple pituitary hormone deficiency (MPHD) are
heterogeneous disorders with several different etiologies and they are responsible for most cases of short stature. Mutations
in different genes have been identified but still many patients did not present mutations in any of the known genes.
Chromosomal rearrangements may also be involved in short stature and, among others, deletions of 18q23 defined a critical
region for the disorder. No gene was yet identified. Methodology/Principal Findings. We now report a balanced
translocation X;18 in a patient presenting a breakpoint in 18q23 that was surprisingly mapped about 500 Kb distal from the
short stature critical region. It separated from the flanking SALL3 gene a region enriched in highly conserved non-coding
elements (HCNE) that appeared to be regulatory sequences, active as enhancers or silencers during embryonic development.
Conclusion.We propose that, during pituitary development, the 18q rearrangement may alter expression of 18q genes or of X
chromosome genes that are translocated next to the HCNEs. Alteration of expression of developmentally regulated genes by
translocation of HCNEs may represent a common mechanism for disorders associated to isolated chromosomal
rearrangements.
Citation: Rizzolio F, Bione S, Sala C, Tribioli C, Ciccone R, et al (2008) Highly Conserved Non-Coding Sequences and the 18q Critical Region for Short
Stature: A Common Mechanism of Disease?. PLoS ONE 3(1): e1460. doi:10.1371/journal.pone.0001460
INTRODUCTION
IGHD and MPHD are endocrine disorders responsible of most
cases of short stature. They may have different etiologies and are
often associated with structural hypothalamic-pituitary (H-P)
defects detectable by neuroimaging [1,2]. Both IGHD and
MPHD may have a genetic origin, as shown by identification of
mutations in genes encoding critical components of the H-P axis.
Two genes, the GH1 encoding the GH and the GHRHR, expressed
along the somatotropic axis and six genes encoding transcription
factors involved in anterior pituitary gland development (POU1F1,
PROP1, HESX1, LHX3, LHX4 and SOX3), have been identified in
patients with GH deficiency [1,2]. However, it is likely that other
genes may be involved in the etiology of GH-dependent short
stature, as the majority of patients did not present mutations in any
of the known genes [3,4].
As it was the case for many other heterogeneous disorders,
chromosomal variations may also be involved in determining the
short stature phenotype. It is well established that relatively
common chromosomal rearrangements associated with short
stature are 18q deletions [5]. The cytogenetic and molecular
localization of the deletions in a large number of patients
demonstrated a common deleted region of about 2 Mb, defined
as the critical region for short stature [6]. The same region was
recently confirmed and precisely defined by array CGH analysis.
In the same study, two additional commonly deleted regions,
localized more proximally along 18q, were identified [7]. In the
few cases when it was tested, the GH deficiency resulted to depend
from a defect in hypothalamic or neurosecretory functions that
control pituitary GH synthesis [5,8]. In only one case a pituitary
malformation was reported [9]. However, the deletion of the
critical region was not always sufficient to cause short stature as a
number of patients presented with stature in the normal range.
Moreover, 18q partial monosomy resulted in variable severity of
the phenotype that did not correlate with the size of the deletions.
Altogether the data may indicate that haploinsufficiency for one
gene in 18q23 may cause GH deficiency and short stature, but that
it likely represents a risk factor rather than a cause for the disorder.
Among the four genes in the critical region (two ZNF proteins
encoding genes, ZNF516 and ZNF236, theMBP and GALR1 genes)
GALR1 was considered the best candidate. GALR1 is one of the
receptors of Galanin, a 29 aminoacid neuropeptide playing a
critical role in many diverse central and peripheral nerve functions
[10]. The biological effects of galanin are mediated by three G
protein coupled receptors, GalR1, GalR2 and GalR3, that show a
widespread distribution throughout the central and peripheral
nervous system and may participate in different aspects of the
galanin function [11]. Their specific role has not yet been
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determined. From the study of a Galr1 KO mice [12] it seems that
it is mainly involved in the neuroprotective action of galanin and
in its anticonvulsant effect, while it does not seem to be involved in
other galanin functions such as nociception. The KO mice did not
appear to have any hypothalamic or pituitary related defects [12].
In conclusion the role of GALR1 in GH deficiency is far from being
clarified but from the phenotype of the KO mice it is not unlikely
that other genes in the region should be considered as candidates
for short stature.
One female patient presenting with GHD and ectopic posterior
pituitary at Magnetic Resonance Imaging (MRI) was described.
She carried an X;18 balanced translocation with breakpoints in
Xq22.3 and 18q23 [13]. The patient had primary amenorrhea,
that had been ascribed to interruption of the Xq Premature
Ovarian Failure (POF) critical region, while the short stature was
related to the 18q rearrangement.
Here we present the fine mapping of both Xq and 18q
breakpoints in the patient and we report that in 18q it was localized
outside and distally from the short stature critical region. It was
mapped 80 Kb upstream from a gene, SALL3, a developmentally
regulated transcription factor that seems to act as downstream
targets of hedgehog. It had been previously considered as a
candidate for different phenotypes associated to the 18q- syndrome,
but not for short stature, as it was not deleted in one patient [5,7].
The analysis of the 18q breakpoint highlighted a gene free region
enriched in HCNEs and indicated that translocation of the HCNEs
itself may be responsible for the patient phenotype.
RESULTS
Fine mapping of the X/18 breakpoints
The 18q breakpoint in the patient 263/96 was mapped by FISH
to a 140 Kb region defined by BAC RP11-496G14, that
hybridized to chromosome 18 and to der18 and by BAC RP11-
850021 that hybridized to chromosome 18 and to derX (not
shown): genome sequence analysis mapped the breakpoint distal
from the GALR1 gene and proximal to the SALL3 gene (Fig. 1a).
The X chromosome breakpoint was similarly mapped by FISH
(Fig. 1). The PAC RP1-302C5, in Xq23, was found to hybridize to
chromosome X and to the two derivative chromosomes [14].
Both breakpoints were defined by PFGE analysis (Fig. 1 c and d).
Genomic DNA of the patient and of controls were digested with the
BamHI and KpnI restriction enzymes to map the 18q and Xq
breakpoints respectively. Genomic probes in the regions hybridized
to BamHI and KpnI fragments of the expected size. The genomic
probe 263/5, from chromosome 18, hybridized to a 15 Kb
fragment in all samples, and to an additional fragment of 26 Kb
in the patient DNA (Fig. 1c) indicating that the breakpoint mapped
less than 15 Kb from the BamHI site and 80 Kb from the 59 end of
the SALL3 gene. The genomic probe 26361 (chromosome X)
hybridized to a 23 Kb fragment in all samples, and to an additional
fragment of 10 Kb in the patient DNA (Fig. 1d) indicating that the
breakpoint mapped 40 Kb downstream from the RGAG1 gene and
180 Kb from the 39 end of the CHRDL1 genes (Fig. 1b).
A genome-wide array-CGH analysis did not show any
additional genomic imbalance, with the exception of known copy
number variations already reported on the Database of Genomic
Variants (http://projects.tcag.ca/variation/). Considering the
average spacing among probes and that at least three consecutive
probes with a shifted log2 ratio are needed to make a call for an
imbalance, we could not identify any deletion larger than 20 Kb,
on average.
In conclusion, none of the breakpoints interrupted a gene and
no other rearrangement was detected in the patient. Moreover the
18q breakpoint mapped outside from the critical region defined
from deletion mapping (Fig. 1a). The distal boundary of the region
was defined by few patients carrying interstitial deletions and
particularly by patient nu13 from Cody et al. [6], presenting a
distal breakpoint between 73.1 and 73.4 Mb, .1 Mb from that in
the patient.
Figure 1. Breakpoint map of the 263/96 patient. a. Map of the 18q
breakpoint region. The position of the breakpoint at 74.8 Mb of
chromosome 18 is indicated by a vertical arrow. Below is a schematic
representation of the deletion map and of the short stature critical
region [6,7]. The position of the markers used is indicated; the critical
region boundaries are indicated by dotted lines. Under the map are the
genes in the region: horizontal arrows represent transcription
orientation. b. Map of the Xq breakpoint region. The position of the
breakpoint at 109.7 Mb of chromosome X is indicated by a vertical
arrow. Under the map are the genes in the region: horizontal arrows
represent transcription orientation. c. Southern Blot analysis of the 18q
breakpoint: DNA from the patient and of two normal DNAs was
digested with BamH1 and fractionated by PFGE as described previously
[31]. The Blot was hybridized with the probe 263/5. d. Southern Blot
analysis of the Xq breakpoint: DNA from the patient and of two normal
DNAs was digested with KpnI and fractionated by PFGE as described
previously [31]. The Blot was hybridized with the probe 26361. Probes
are described in Materials and Methods. Map positions are from NCBI
Release 36.1
doi:10.1371/journal.pone.0001460.g001
HCNE and Disease
PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1460
Comparative genome analysis of the breakpoint
regions
To find an explanation for the phenotype of the patient, we looked
for evolutionary conserved non-coding sequences that may have a
regulatory function on gene expression. We compared the DNA
sequences flanking the patient breakpoints to the syntenic regions of
mouse, chicken and fugu utilizing the VISTA Genome Browser
(http://genome.lbl.gov/vista/index.shtml). No highly conserved
sequences were found at the Xq breakpoint region. On the other
hand, in the 2 Mb gene free region between GALR1 and SALL3
several highly conserved non-coding elements (HCNE), could be
detected [15,16,17]. Among the HCNEs, 11 presented 100%
identity over 100 bp between human and mouse and at least 97%
identity over 100 bp between human and chicken (Fig. 2). They
were clustered in a 700 Kb region, 500 Kb centromeric to the
SALL3 gene. All were localized about 500 Kb distal from the short
stature critical region and distal in respect to an ‘‘evolutionary
breakpoint’’ at 73.5 Mb of human chromosome 18, where synteny
between chicken and mammals ended (Fig. 2). None of the HCNEs
could be defined ultraconserved (UCR), e.g. presenting 100%
identity between human and mouse for at least 200 bp [15,16].
However some were highly conserved in Fugu: HCNE 2, 6, and 7
had .85% identity for .100 bp between fugu and human (Fig. 2).
Functional analysis of the HCNEs
HCNEs were previously shown to have enhancer function [18].
Seven of the HCNEs in the region (HCNE1, 3, 6, 7, 8, 9 and E, in
Fig. 2) were cloned into the pGL2 luciferase vector [19], upstream
of the SV40 promoter and tested in different cell lines. As shown in
Fig. 3, three of the HCNEs had indeed enhancer activity and
increased the luciferase activity from 1.5 to 3 times compared to
the promoter only construct (P) in Hela and COS cells. HCNE 1,
9 and E demonstrated enhancer activity in COS cells: HCNE 1
and E more than doubled the luciferase activity. HCNE 9 had a
lower enhancer activity (1.5 times the promoter only construct)
that was maintained in Hela cells. In a third cell line, P19, of
neural origin, none of the HCNEs had enhancer activity, but
HCNE 1 and HCNE 9 significantly decreased the luciferase
activity, behaving as gene silencers.
From these in vitro experiments we can conclude that the
HCNEs upstream from the SALL3 gene may be regulatory
elements controlling the expression of genes in the region either as
enhancer or silencers.
Chromatin modifications of HCNEs during mouse
development
HCNEs were often found in the vicinity of developmentally
expressed genes and it was shown that they may be developmental
specific enhancers [18]. It was also shown that in embryonic stem
cells HCNE rich loci presented a characteristic chromatin
modification pattern, termed ‘‘bivalent domain’’ consisting of
large regions of tri-methyl-lysin 27 histone 3 (3MK27H3)
harboring smaller region of di-methyl-lysin 4 histone 3
(2MK4H3), suggestive of a poised state for activation [17].
We analyzed by chromatin immunoprecipitation (ChIP) the
acetylation of histone H3 (acH3) and H4 (acH4), and the methylation
of K4 and K27 of histone H3 (2MK4H3 and 3MK27H3) of all the
HCNEs in mouse embryo at E11.5 (Fig. 4a) to look for
developmentally regulated histone modifications. Two controls, the
promoters of the expressed genes Myc and Xist, were modified as
expected by the active chromatin modifications, acH3, acH4 and
2MK4H3. Two HCNEs, HCNE3 and HCNE7, were found
enriched in some of the histone modifications analyzed. HCNE3
was enriched in acH3 and 2MK4H3: it appeared to have an open
chromatin conformation and it may be therefore an active enhancer
at E11.5. HCNE7 was enriched for both 2MK4H3 and 3MK27H3
and may thus present the bivalent domain previously described for
developmentally regulated HCNE. The same chromatin organiza-
tion was found also at the promoter regions of the Sall3 and Chrdl1
genes (on mouse chromosomes 18 and X respectively) both flanking
the breakpoints in the 263/96 patient and expressed at early
developmental stages in the mouse [20,21,22]. A third gene analyzed,
Atp9b, localized distally from Sall3 but ubiquitously expressed,
presented only open chromatin modifications.
For comparison we studied adult mouse brain (Fig. 4B). All the
HCNEs were negative for open chromatin modifications and
therefore they may not be active. Accordingly, many of the
HCNEs (1, 3, 7, 9) showed high level of 3MK27H3, suggestive of a
closed chromatin modification. All promoter regions had in adult
brain the same modifications shown for E11.5.
In conclusion, as summarized in Table 1, the HCNEs between
Galr1 and Sall3 appeared to be highly regulated elements,
presenting an open chromatin conformation only during early
Figure 2. Comparative analysis of the HCNE rich region in 18q. The portion of the analysis from the VISTA Genome Browser (http://genome.lbl.gov/
vista/index.shtml) from 73,5 to 75 Mb of human chromosome 18 is reported to show conservation between human and mouse, chicken or fugu. The
HCNEs are numbered above the peaks. The position of the 263/96 breakpoint is indicated by a vertical arrow, that of the genes SALL3 and ATP9B by a
horizontal arrow. The homology between human and the species indicated is shown on the right (%). Map positions in human correspond to NCBI
Release 35.
doi:10.1371/journal.pone.0001460.g002
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stages of development. They seem to acquire a closed conforma-
tion in the adult, where they are presumably inactive.
Sall3, Chrdl1 and Atp9b expression during mouse
embryo development
The chromatin results suggested that the chromosomal rearrange-
ment in the patient with GH deficiency might alter the expression of
developmentally expressed genes flanking the breakpoints. The Sall3
gene on chromosome 18 and the Chrdl1 gene on the X chromosome
have been reported previously to have a developmentally regulated
expression [20,23]. Analysis by real time RT PCR (Fig. 5) confirmed
that Sall3 is expressed at high level in mouse embryo until E15.5. At
later stages it is down regulated and in the adult is expressed only in
few tissues, brain and kidney among the one tested. It is not
expressed in the adult pituitary. Also the Chrdl1 on the X
chromosomes is expressed at early developmental stages (E8) and
only in some tissues in the adult. The third gene, Atp9b, distal from
Sall3 on mouse chromosome 18 was rather ubiquitously expressed in
embryo and in all adult tissue analyzed (Fig. 5). Both Atp9b and
Chrdl1 are expressed at very low level in the ovary.
We analyzed expression of the three genes by in situ
hybridization in the ovary and in the developing pituitary. In situ
hybridization failed to show any specific hybridization in the
ovarian follicle in adult (P20) mice and in E16.5 (not shown) that
Figure 3. Some of the HCNEs have enhancer or silencer function.
Luciferase report assays of the cell lines indicated, transfected with
constructs containing promoter only vector (P), a conserved elements
from a different genomic region, showing enhancer activity (EN), an
unrelated negative control (UR: human/mouse non-conserved ele-
ment), HCNE1, 9 and E as in Fig. 2. All values are expressed as % of the
luciferase activity of the promoter vector (P). *: p value,0.001.
doi:10.1371/journal.pone.0001460.g003
Figure 4. ChIP of the HCNE on total E11.5 chromatin and adult mouse
brain. Embryonal (a) and adult brain chromatin preparations (b) were
immunoprecipitated with the antibodies to the histone modifications
indicated on the X axis and the DNA was PCR amplified with primers
specific for each HCNE. INP: PCR from total chromatin. AcH3 and acH4:
ChIP with antibodies to acetylated histone H3 or H4. 2MK4H3: ChIP with
antibodies to 2-methyl K4 of histone H3; 3MK27H3: ChIP with
antibodies to 3-methyl K27 of histone H3. All values are fold increases,
compared to an equal amount of INP. Myc, Xist (positive controls),
Atp9b, Sall3 and Chrdl1 indicate primers in the 59UTR region of each
gene. Only HCNEs positive for at least one modification were reported
in the figure.
doi:10.1371/journal.pone.0001460.g004
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could account for the POF phenotype of the patients. In situ
hybridization failed to show expression of the Sall3 gene in at all
stages of the developing pituitary, E9.5, E10.5, E12.5, E14.5 and
E17.5 (not shown). The Chrdl1 was faintly expressed in the
pituitary at E17.5. Atp9b was expressed at low level at E14.5 and
E17.5 (not shown).
In conclusion, as summarized in Table 2, the three genes
appeared expressed during development and their regulated
expression may be controlled or altered by the presence of
flanking HCNEs.
The chromatin of the SALL3 and ATP9B genes was
altered in the lymphoblastoid cell line of the
patients
Chromatin prepared from the patient 263/96 and two normal
lymphoblastoid cell controls was analyzed to establish whether the
rearrangement might alter the organization of the promoters of
the genes in the vicinity of the breakpoints. Antibodies to acH3,
acH4 and 2MK4H3, markers of active chromatin state, were used
for ChIP. The analysis was done by real time PCR with primers in
the promoters of the genes flanking the breakpoints. Since the
average chromatin modification level was not identical in different
cell types, to compare results between different cell lines, we
calculated the ratio of acH4/acH3 and acH4/2MK4H3 in each
cell line (Fig. 6). We could not find chromatin modification in the
promoter regions of the X chromosome genes RGAG1 and
CHRDL1 nor for the GALR1 gene. We were able to analyze SALL3
and ATP9B genes and the genes more distant on chromosome 18
(MBP at the proximal side and NFATC1 at the distal side).
Translocation to the X chromosome critical region of SALL3 and
ATP9B caused a reduction of the acH4 modification compared to
the controls (Fig. 6). AcH3 and 2MK4H3 were unchanged.
DISCUSSION
The results report the molecular analysis of the critical region for
short stature in 18q and highlight a novel mechanism of disease
that may be rather common when genomic regions presenting
high evolutionary conservation [15] are involved in chromosomal
rearrangements.
In the analysis of a X;18 balanced translocation in a patient
affected with GHD and ectopic posterior pituitary, we were
surprised to find that the 18q breakpoint did not interrupt the
short stature critical region in 18q23 [6,7]. Rather, it mapped
about 1 Mb distally and 80 kb upstream from the SALL3 gene
promoter, at a first glance, pointing to SALL3, a gene outside of the
critical region, as the candidate gene for the phenotype. To
reconcile the contradictory data coming from the molecular
definition of the chromosomal rearrangements we report here the
observation of 11 HCNEs, presenting 100% conservation for at
least 100 nt among mammals and .97% with chicken. All were
clustered within 700 Kb where many highly conserved elements
were present .90% identical within mammals. The HCNE
cluster was localized in a gene desert between the promoter of
SALL3 and the GALR1 gene: its proximal end, at about 73.6 Mb of
chromosome 18, corresponded to the point where the synteny with
chicken ended (Fig. 2). The data indicated that the HCNEs may
be evolutionary conserved controlling elements of the SALL3 gene,
as it was suggested also by the finding of HCNEs in a similar
position in two other members of the SALL gene family, SALL1
and SALL4 [18,24].
Table 1. Summary of HCNE characteristics
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCNE Enhanceru Silenceruu Chromatin modification*
E11.5 Adult brain
HCNE1 yes yes none detectable inactive
HCNE3 no no active inactive
HCNE7 no no active and inactive inactive
HCNE9 yes yes none detectable inactive
HCNEE yes no none detectable none detectable
uin COS and Hela cells
uuin P19 cells
*active: AcH3 and 2mK4H3; inactive: 3mK27H3
doi:10.1371/journal.pone.0001460.t001..
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Figure 5. Real time RT-PCR of the Chrdl1, Sall3 and Atp9b genes in
mouse tissues. RNAs from the tissues and the developmental stages
indicated on the X axis were reverse transcribed and PCR amplified as
described in Materials and Methods. Each value was normalized as
described in Materials and Methods and the ratio with the histone H3
gene expression was calculated.
doi:10.1371/journal.pone.0001460.g005
Table 2. Summary of gene characteristics at E11.5
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Genes Chromatin modification* Gene expression
whole embryo^ pituitaryu
Sall3 active and inactive yes no
Atp9b active yes(low) no
Chrdl1 active and inactive yes(low) no
*active: AcH3 and 2mK4H3; inactive: 3mK27H3
^
By real time RT-PCR; comparison were with histone H3 mRNA
uBy in situ hybridization
doi:10.1371/journal.pone.0001460.t002..
..
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..
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HCNEs were often found in the vicinity of developmentally
regulated genes and have been shown to function as developmen-
tal specific enhancers in several systems [18]. It was suggested that
they may work by binding transcription factors and/or as
organizers of genomic architecture around developmental genes.
Indeed, the genes distal from the HCNE cluster, SALL3 and
ATP9B, were expressed early during development in the mouse
starting from E8, the earliest stage studied. While the function of
ATPB is not known, SALL3, a member of a family of genes with
homology to the spalt gene of Drosophila melanogaster, was parti-
cularly interesting. Spalt genes encode transcription factors that in
Drosophila act as downstream targets of hedgehog [25]. Sal-like
genes were identified in vertebrates and they are all expressed
during embryonic development: it was suggested that they may
dictate the nuclear localization for correct gene transcription [24].
Finally, mutations in two members of the family (SALL1 and
SALL4) are responsible of human developmental disorders [25].
Our data is consistent with the idea that the HCNEs in 18q23
may function as enhancers (as in Hela or COS cells) as well as
silencers (as in P19 cells), depending from the cell type considered.
Analysis of chromatin modifications [26] demonstrated that, in
mouse embryo chromatin at E11.5, some of the HCNEs presented
active chromatin modifications that were absent in adult animals.
One, HCNE3, had an active only chromatin state, and may thus
carry an open chromatin conformation in most cells at the E11.5.
The other, HCNE7, showed a bivalent domain of modifications
with enrichment for both 2MK4H3 and 3MK27H3. This may
results from chromatin in a poised state for transcription as
suggested previously [17] or from different chromatin organization
in the different cells of the E11.5 embryo. In any case, we can
conclude that the HCNEs in the region are developmentally
regulated enhancers/silencers, that may up or down regulate
expression of flanking genes in a cell and stage specific way, as
shown in vivo for similar genomic regions [18]
Among the genes in the region, SALL3 was highly expressed in
brain and it was previously suggested that it may be involved in
determining some of the neurological phenotypes of the 18q
deletion syndrome such as mental retardation, hearing loss,
ophthalmic abnormalities [7]. In agreement with the finding that
haploinsufficiency for SALL3 does not seem to be involved with
short stature, we show here that Sall3 did not appear expressed in
the developing nor in adult pituitary. We therefore propose that
the balanced translocation will cause ectopic expression of SALL3,
and possibly of distally flanking genes, in the pituitary through
elimination of a silencing effect of the HCNEs. A similar mutation
was demonstrated for the Shh gene whose ectopic expression in the
anterior limb of the mouse was due to insertions about 1Mb
upstream from Shh. The region contains a conserved non-coding
element that can function as enhancer as well as a repressor and
drives Shh expression in the limb. Its rearrangement was
responsible for the phenotype of mouse mutants presenting with
limb defects [27]. The 18q23 HCNEs may be the first example of
such effect in a human disorder.
The phenotype of the patient could be due also to a more complex
effect of the HCNEs, as a second interesting gene, was involved in
the rearrangement, CHRDL1. The CHRDL1 gene on the X
chromosome encodes for an inhibitor of BMP signaling through its
cysteine-rich repeats. Its expression pattern coincides with that of
some members of the BMP signaling pathways [28], a large
subgroup of the transforming growth factor beta superfamily, that
serve key roles in stem cell fate commitment. Interestingly, some of
the members of the BMP family (BMP4 and BMP2) appear to be
involved in the Rathke’s pouch formation [29] and pituitary
development. In the mouse, the Chrdl1 gene was expressed at low
level in the pituitary at late stages of development and in the adult.
Once translocated downstream to 18q23, this low level of expression
in the pituitary could be either inhibited or enhanced by the
upstream HCNEs. Deregulation of expression of CHRDL1 and
SALL3 could therefore be factors in determining the phenotype of
the patient. Moreover, it could explain the pituitary ectopia which is
not a common feature of the GH deficiency and short stature, as it
was described only once in the 18q- syndrome [9].
The X;18 patient had hypergonadotropic primary amenorrhea
and ovarian dysgenesis [13]. Due to the involvement of X
chromosome POF critical region we searched for candidate genes
in this locus. As previously occurred in other parts of the POF
critical region [14,30] no genes with clear ovarian expression
could be identified on the X chromosome, 500Kb to 1Mb from
Figure 6. Chromatin modifications of genes flanking the 18q break-
point, in the LB263/96 patient. Chromatin of the patient 263/96 and two
normal lymphoblastoid cell lines was IP with antibodies to acH3, acH4 or
to 2MK4H3 and the DNA was amplified by real time PCR with primers in
the promoter regions of each gene. One or two sets of primers were
utilized for each gene, as indicated. Modifications were calculated as
described in Materials and Methods. In the figure, the ratio between acH3/
acH4 (black) and acH4/2MK4 (gray) in chromatin from the LB263/96
patient and two normal controls (MA and LB696) is shown.
doi:10.1371/journal.pone.0001460.g006
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the breakpoint. However also in the 18q23 breakpoint region no
genes highly expressed in the ovarian follicle could be found (not
shown). It is therefore not unlikely that the 18q23 HCNEs could
have a role also on the POF phenotype through ectopic expression
of some of the genes involved in the breakpoint in the ovary and
particularly in the ovarian follicle. The changes in chromatin
modifications observed at the SALL3 and ATP9B genes in patients
lymphoblastoid cells may due to lack of the HCNE region
upstream and of its controlling elements and support the
hypothesis that chromatin alterations may be associated to the
involvement of the HCNEs in the rearrangement.
In conclusion, the analysis reported indicated that the
phenotype of the patient 263/96 could be the consequence of
the involvement of HCNEs in the chromosomal rearrangement.
Due to the abundance of HCNEs in the human genome [15,16],
we suggest that it might represents the first example of a common
mechanism of disease, associated to isolated chromosomal
rearrangements. In all cases when no gene involvement can be
demonstrated we suggest that HCNEs should be searched.
MATERIALS AND METHODS
Case
The girl, 263/96, was first seen at 3.2 years of age because of short
stature. Her clinical characteristics were previously reported [13].
Clinical examination revealed no dysmorphic features, but a
phenotype suggestive of congenital GHD including doll-like
appearance with frontal bossing, poor development of the nasal
bridge and increased adipose tissue of the trunk. Height was ,23
SDS and endocrine investigations were compatible with IGHD. At
the time of puberty, primary amenorrhea, hypergonadotropic
hypogonadism and ovarian dysgenesis were also found. Chromo-
some analysis on cultured lymphocytes and skin fibroblasts
revealed that the patient carried a de novo X/18 translocation
(46, X, t (X, 18) (q22.3, q23),inv(9)(p11q13). MRI of the H-P
region showed posterior pituitary ectopia, anterior pituitary
hypoplasia and pituitary stalk agenesis.
Written informed consent was obtained from the patient. The
study was approved by the Institutional Review Board of the
Policlinico San Matteo and the part regarding POF also by the
Ethical Committee of the San Raffaele Hospital.
Lymphoblastoid cell line of the patient and of normal controls
were grown as described [31].
FISH mapping of the breakpoints
The 18q and Xq breakpoints in the patient 263/96 were mapped
by FISH as described [32] using PAC and BAC clones from the
Ensembl contig map (http://www.ensembl.org/). Fine mapping
was done by Pulsed Field Gel Electrophoresis (PFGE) using
restriction enzymes producing 50–100 Kb restriction fragments in
genomic DNA [31]. Fragments were identified by Southern
Blotting and hybridization to radioactively labeled probes
prepared by PCR amplification of repeat free regions of genomic
DNA (chr.X: 26361F 5-GACACACTCTTAACACTGAGC and
26361R 5-AGCTGATGGCTAGGAGAACC; chr.18: 263/5F 5-
CATGCACGATACATCTGACC and 263/5R 5-AGAGGAGA-
CAGAACATCTGG)
Whole genome array-CGH
Whole genome array-CGH was performed by using the Agilent
244 K chip (Agilent Technologies, Palo Alto, CA, USA) according
to the manufacturer’s protocol. This genome-wide chip has an
average resolution of about 20 Kb. Reference and patient DNAs
were double-digested with RsaI and AluI for two hours at 37uC and
labeled with the with Cy3-dUTP and Cy5-dUTP respectively.
After column purification, the two differentially labeled DNAs
were combined, denaturated and pre-annealed with 50 mg of Cot-
1 DNA. Hybridization was performed at 65uC with rotation for
40 hours. After two washing steps, images of the arrays were
acquired with the Agilent scanner and analyzed by using the
Feature Extraction software (v9.1). A graphical overview of the
results was obtained with CGH Analytics software (v3.4).
Chromatin preparations and immunoprecipitation
Tissues were cut in small pieces in cold PBS 16 and fixed in 1%
formaldehyde for 20 min at room temperature (RT). Lymphoblas-
toid cell lines were fixed in RPMI containing 1% formaldehyde for
20 min at RT. The reaction was quenched with 125 mM glycine
and the cells pelletted. Brain pieces were homogenized with a
douncer, centrifugated at 1200 rpm 59 at RT, resuspended in cell
lysis buffer (100 mMTrisHCl, 10 mMNaCl, 0.2% NP40) for 109 in
ice, centrifugated at 5000 rpm 59 at RT, resuspended in Lysis Buffer
(1%SDS, 10 mM EDTA pH8, 50 mM Tris-Hcl pH 8.1, 1 mM
PMSF (Phenylmethylsulphonyl fluoride)) and sonicated with a
XL2020 sonicator microtip (Misonix Incorporated) 20% power for
150s, to break DNA in chromatin to a size between 500 and
2000 bp. Chromatin was diluted 10 times in DB buffer (1% Triton,
2 mM EDTA pH 8, 150 mM NaCl, 20 mM Tris-Hcl pH 8.1,
1 mM PMSF). 100/200 mgr of chromatin was immunoprecipitated
with 2 ml of antibody specific for acetylated histone H3 (Upstate
Biotechnology, Billerica, MA, USA (UB 06-559)), 5 ml acetylated
Histone H4 (UB 06-866), 5 ml di-methylated Lys4 Histone H3 (UB
07-030) and 5 ml tri-methylated Lys27 Histone H3 (UB 07-449), ON
at 4uC and then mixed with 20 ml protein A sepharose beads (GE
Healthcare, UK) saturated ON at 4uC with 500 mg of salmon sperm
DNA and 100 mg of BSA and incubated for 3h at 4uC with gentle
rocking. In parallel, immunoprecipitations with an unrelated
antibody (anti urokinase plasminogen activator receptor) or no
antibodies (Mock) were also performed as control. Beads were
washed 5 times with Wash buffer (0.1% SDS, 1% Triton, 150 mM
NaCl, 20 mM Tris-HCl pH 8.1, 1 mM PMSF) and 3 times with
Final wash (0.1% SDS, 1% Triton, 2 mM EDTA, 500 mM NaCl,
20 mM Tris-HCl pH 8.1, 1 mM PMSF). Bound chromatin was
eluted with 1% SDS and 0.5 mgr/ml Proteinase K for 3 hours at
50uC. DNAwas de-crosslinked ON at 65uC and purified by phenol/
chloroform extraction.
Real time PCR and data analysis
DNA was analyzed by Real time PCR with Syber Green Universal
Mix (Sigma-Aldrich, St.Louis, MO, USA) on a Light Cycler 480
(Roche Diagnostic, Basel, Switzerland). Total DNA, IP DNA and
Mock IP DNA were quantified using picogreen (Molecular Probes,
Carlsbad, CA, USA) and equal amounts of DNA (0.5 ng) were
used in PCR. Samples were run in duplicate and each experiment
was repeated two to five times, on independent preparations. Data
quantification was done as described by Litt [33]. In brief, we
determined the quantity of the template at the Ct (target cycle) and
the efficiency (X) by a internal standard control and the fold
increase was calculated as X(inputCt-IPCt). All the values were
corrected for nonspecific signal, by subtracting the values of Mock
IP. All the PCR primers are listed in Table S2 in supplementary
information.
Transient transfection and luciferase reporter assay
HCNE were amplified from human DNA with PFU DNA
polymerase (Stratagene, La Jolla, CA, USA) and cloned into pGL2
promoter vector (Promega, Madison, WI, USA) utilizing MluI and
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XhoI primer adaptor sequences (Table S1 in supplementary
information). All clones were sequence verified.
DNA transfections were carried out using Lipofectamine 2000
following manufacturer’s instruction (Invitrogen, Carlsbad, CA,
USA). For luciferase reporter assay, cells were seeded in 96-well
plates 24 h before transfection in DMEM, 10% fetal bovine
serum. They were transfected at 90% confluence with 250 ng of
plasmid/well, and 5 ng of renilla vector (Promega, Madison, WI,
USA). 24 hours after transfection, the cells were harvested and the
luciferase activity was determined using Dual-Glo luciferase assay
system according to manufacturer’s instructions (Promega,
Madison, WI, USA). Luciferase activities were normalized to the
renilla vector activity. Statistical analysis was done utilizing two
tailed Student t test.
RT-PCR and Real Time PCR
Total RNA was prepared from tissues using the RNA extraction
kit Rnaeasy (Qiagen, Germany). One mg of total RNA was reverse
transcribed in a 20 ml reaction using M-MLV reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). Primers for amplification of
Atp9b, Sall3 and Chrdl1 are listed in Table S3, in supplementary
information. Quantitative Real Time PCR (qRT-PCR) was
performed with SYBR Green PCR Master Mix (Sigma-Aldrich,
St.Louis, MO, USA) in a Light Cycler 480 (Roche Diagnostic,
Basel, Switzerland). Samples were run in triplicates and the
efficiency of each primer was calculated utilizing an internal
standard control. All values were normalized for histone H3.
In situ hybridization
In situ hybridizations were done as described [34].
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